new richest man, Li Li-promotion: 42600000000 How to Make Fortune
April 27, 2010 08:0221 Century Business Herald
Li Li (Source: Data Chart)
Hai Purui [0.00
0.00%] (002399.SZ) released high price, the new richest man, Li Li, turned from the sky.
From April 26, Hai Purui 148 yuan per share offering price, few people know of this bio-pharmaceutical company almost broke into the eyes of all investors. Its founder, Li Li, Li Tanfu women’s total holding 28,803.7 million shares, to issue price of its net worth was 42.629 billion yuan, topped the mainland’s richest man.
This is a classic private family business, actually controlled by Li Li, Li Tanfu women, two were appointed chairman and director Haipu Rui, deputy general manager, director, general manager of single-Yu Tan’s elder brother Lee.
In 1998, Li Li co-founded Hai Purui their families, and hard not started in this business, 10 years earlier, wandering in Sichuan, Chongqing, Li Li, a time to search for products and solution production run into a wall or compromises, Finally, the opportunity came from a meeting with Southwest Pharmaceutical [14.77
3.79%] cooperation, Li Li uncovered pot of gold.
Bodiless Chongqing China Star
December 26, 1997, southwest of West Chongqing pharmaceutical medicine will be transferred to their respective Begonia New Materials Co., Ltd. in Chongqing, the transfer payment received 23.2 million yuan for the formation of bio-technology Co., Ltd.. That year, 1997, Southwest Pharmaceutical raise funds through placement of shares 34.79 million yuan.
Journalists access to information learned, Southwest Pharmaceutical Products joint venture established biotechnology company in Chongqing huaxing biological technology limited liability company
The company registered capital of 50 million yuan. Southwest Pharmaceutical companies which invested 34 million yuan, accounting for 68% of shares; Chongqing Huayin Leasing Co., Ltd. invested 15 million yuan, accounting for 30% of the shares, while another partner for the Chongqing Tongda Biological Products Co., Ltd., invested one million yuan only 2% ratio.
Southwest Pharmaceutical year according to the notice said, Chongqing huaxing biological main biological products, pharmaceutical technology, product development, from marketing and technical services, chemical products and raw materials, medical devices and equipment.
Chongqing Tongda biological products shall be the earliest start-Li Li-platform. According to business information in Chongqing, Chongqing Tongda Biological Products Co., Ltd. was established in 1990, the legal representative of the Li Li, location for the Jiulongpo District Branch Chong Road, No. 6, registered business scope is currently the main Haipu Rui Pharma business operations: production, sales of heparin sodium API.
Li Li was born in 1964, in July 1987 graduated from the Department of Chemistry, Sichuan University, Chengdu, meat processing before being assigned to work.
October 1992, Lee left the state-owned units of lithium, heparin, and Chongqing Tongda cooperation project contract. Chongqing Tongda Trade Co., Ltd. in Chongqing China Shanghai, Chongqing City Construction Investment Corporation of Shenzhen City, China Business Sources Joint Industrial Development Co., Ltd. and Hong Kong co-Shun Industrial Co., Ltd., Chongqing Kebo Technology Co., Ltd. jointly established by Li Li is directly responsible for management, served as chief engineer, chairman and managing director.
According to national gold stock [17.50
-4.27%] Pharmaceutical analyst Hao Pei-yu’s research and analysis on the end of the century the rise of modern biotechnology and microelectronics, new materials and new energy technologies are considered the core of 21st century science. The development of modern biotechnology to the development of the pharmaceutical industry was opened up a new new areas. Since 1995, the majority of domestic pharmaceutical companies are attracted into the field.
According to Southwest Pharmaceutical public information display, Chongqing huaxing material that is year 1998 profit of 3.28 million yuan. October 2000, Southwest Pharmaceutical increase biopharmaceutical investment, joint venture invested 3,687,600 yuan acquisition of innovative bio-engineering Co., Ltd. Chongqing, representing the total shares of joint venture 65% of Singaporean Chinese Cui Taian funding equivalent to 150 million, composed of proprietary technologies and equipment as investment, accounting for the remaining 35% stake.
Chongqing, Chongqing huaxing biological and bio-innovation with the office, staff leadership and management by the same class after 2000 gradually involved in litigation with the Southwest medicine, there is no Qingli business.
“Chongqing huaxing material was mainly to do some biomedical research, no real business was already.” Southwest Pharmaceutical securities Zhou Xia said. In 2008, despite the Chongqing huaxing biological systems by the Chongqing Science and Technology Committee approved hi-tech enterprises, 15% of the income tax benefits applicable to the southwest medicine only dividends from the company 172,889 yuan.
Secondary leave transfer
As inadequate investment in Chongqing huaxing biological follow-up and operation of fatigue, there is no right to speak, Li Li decided to withdraw from the cooperation of Southwest medicine, their own businesses. “Ten years ago, Li Li and his Biological Products Co., Ltd. Chongqing Tongda have to find the door, asked with me. Unfortunately, this did not arouse enough attention to me.” Provisional Capital chairman Tang Liangping pharmaceutical companies to local reporters said.
According to Tang Liangping introduction, Lee entered the reach of lithium in Chongqing, biological products, has just started, mainly engaged in the extraction of heparin from pig intestine of business. There was provisional capital plant and equipment, pharmaceutical, biological expectations and Tang Liangping Chongqing Tongda cooperation. Provided by the accessibility of biological technology and raw materials, plant and equipment to provide the Provisional Capital medicine, joint production of both heparin API. After Tang Liangping refused.
Tang Liangping that heparin is used to produce the anti-clotting drugs, and later in the 80s of last century when the discovery of hepatitis have a good effect. Although known for more than 70% can be effective, but then, through a large clinical trial revealed that the effect of less than 30%. Therefore, the Tang is not optimistic about the project.
Since then, Li Li once again out of Chongqing Tongda biology, in April 1998 set up the Hai Purui registered in Shenzhen in 1998, Chongqing Huaxing Ying Lee 3.28 million yuan, accounting for only 2% of Chongqing Tongda biological proportional only get less than 7 million in dividends. The Hai Purui registered capital of 200 million, by Li Li, Li Yu Tan and three single-input.
September 1998, Lee met his life lithium Bole, that source of government investment in Shenzhen, Yang Xiangyang. In 1997, Yang Xiangyang biological treatment because they do invest in new drug development for cancer and lost, then, embarked on the road biomedical investment, Shenzhen has become one of the early PE investors, and focus on biomedicine.
Over the past 10 years, Yang Xiangyang has invested a billion dollars in the areas of investment projects in the past 10 months, including SiBiono, Tsinghua Lite, Tsinghua genes City, Hai Purui and North Branch biological.
Year in November, political sources of investment to Hai Purui put six million yuan, together with the original shareholders to increase their investment, so the company capital increase to 20 million yuan, sources of government investment accounted for 30% of the shares. According to Hai Purui prospectus shows Hai Purui profit in 2000, and received the Shenzhen High-tech tax incentives.
In 2000, Chongqing, Southwest China Pharmaceutical Mastery no longer engaged in cooperation with the major R & D products, “Heparin” production and operation, in August 2003, SFDA approved drug approval number changes to Shenzhen Hai Purui, until February 2008 after the cancellation period, Chongqing Tongda not engaged in any production activities, therefore, Southwest Pharmaceutical investment in Chongqing China Star subsequently disappeared.
In 2003, Chongqing was originally part of the bio-accessibility of medicines after approval, Hai Purui entered the stage of rapid development of Chongqing Li Li completely out of bio-accessible. Business registration information, Li Li of the Chongqing Tongda biological products on February 27, 2008 off.
In 2007, Hai Purui welcomed wholly owned subsidiary of Goldman Sachs GS
Pharma. September 3, 2007, Hai Purui Pharmaceutical Council accept the GS Pharma shareholders of the company capital increase 4,917,600 U.S. dollars; the completion of capital increase, GS
Pharma shares were held by Hai Purui Medicine 1125, holds 12.5% stake. Among them, 4.9088 million U.S. dollars equivalent to 36.8823 million yuan included in the registered capital.
Calculated according to the prospectus, the foreign shareholder GS
Pharma profit 6.589 billion yuan is expected to float, about 93 times earnings. As of April 2010, Hai Purui’s largest shareholder Lok Yan technology, its shareholders holding 99% stake in Li Li, Li Tan holds a 1% stake; the company’s second-largest shareholder of Golden Land technology, its shareholders Lee Tan holds a 99% stake held by 1% stake in Li Li; the company’s fourth-largest shareholder Audio Bible technology, its shareholders holding 99% stake in single-woo, Lee holds a 1% stake in Tanzania; the company’s fifth-largest shareholder of flying stones and Technology is wholly owned by Li Li. At present, Li Li couples still hold shares of the total combined 79.97% share capital.
Conference and Scientific Development of Chinese Enterprises in China to promote innovation management project
Management Forum 2010 high-end training program co-application form [download]
Equivalent level for the United States harbor Ph.D., master’s degree program
Eastern Management “Chinese culture and a harmonious enterprise culture” Advanced Training Class on
China (urban) cooperative program of strategic human Fortune Forum
I Ching Chinese culture and business intelligence strategy of scientific development will be the national senior training
Dry spring called: Chinese companies are currently the biggest crisis in human crisis
Taoism talks with entrepreneurs wealth wisdom
Chinese culture and business management transformation and innovation expert public speaking tour live …
Chinese culture and management experts say the national tour and other public solicitation agent
Dry spring: What is Chinese culture?
Chinese Studies and Business Administration (dry spring) high-end training programs
Book of Changes and Management (dry spring) Lecture Series
Ching Innovation and Enterprise Management Training Project Cooperation
National 653 Project and harmony of Chinese culture corporate culture training
Chinese culture and a harmonious enterprise culture Senior Seminar Course Outline
Dry spring: the pain of China’s enterprise management is the human pain
Dry Spring: How to improve employee loyalty SMEs
Students to succeed in business and career planning public speaking tour
Chinese culture and management scholars dry spring
Ching Innovation and Enterprise Management Training Project Cooperation
“The Art of War” and the decision-making leadership training program of senior professional managers